Sign In
Buy INCY
$119.80
-0.800 (-0.663%)
At Close: Aug 05, 2026
Dow Taps Record as Nasdaq, Chips Pull Back
11:47am, Thursday, 02'nd Jul 2026
Stocks are trading mixed as chip stocks weigh and investors digest a fresh batch of June nonfarm payrolls data
INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura
02:41pm, Monday, 29'th Jun 2026
Incyte shares hit a 52-week high as Opzelura gains regulatory momentum, pipeline advances and a CMS settlement boosts investor sentiment.
Incyte (INCY) Surges 5.8%: Is This an Indication of Further Gains?
10:55am, Monday, 29'th Jun 2026
Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t
Incyte: New Catalysts Support Another Leg Higher
08:35am, Monday, 29'th Jun 2026
Incyte Corporation remains a strong long pick, with a maintained 'Buy' rating and a 40% upside to a $159.5/share price target. Recent catalysts include a positive CHMP opinion for Opzelura in Europe a
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positi
MORGES, Switzerland--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis.
Futures are trading mixed as we prepare to finish the last full week of the second quarter.
Why Incyte (INCY) is a Top Momentum Stock for the Long-Term
10:51am, Friday, 19'th Jun 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Japan Announces Approval of Minjuvi (tafasitamab) in Combination with Lenalidomide for Adults with Relapsed or Refractory DLBCL.
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
07:51am, Wednesday, 17'th Jun 2026
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
04:56am, Tuesday, 16'th Jun 2026
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review
11:45am, Monday, 15'th Jun 2026
Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.
Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced pivotal Phase 2 results from Cohort 1 of the PROGRESS study evaluating zilur
FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in FOP.
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-
